SPECIAL ISSUE - AGOlive Event: Prostate (Part1): Prostate radiation in metastatic setting
A. Girlando
Vol.6 (2021), issue 2, pag. 77 - 81
| Received | 23/08/2021 |
| Accepted | 1/09/2021 |
| Published | 07/09/2021 |
| Review by | Single-blind |
| DOI | https://doi.org/10.48253/AGO13 |
ABSTRACT
Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic out- comes depending on several individual- and disease- speci c char- acteristics.
Designing trials for such a various population is challenging yet nec- essary to improve treatment ef cacy; the role of local therapy as a sole therapy or part of a combined approach in treating metastatic cancer continues to evolve.
The most obvious requirements for prudent implementation of local therapies such as stereotactic ablative radiotherapy (SABR) to be- come mainstream in treating oligometastases are, one, clear guid- ance on what type of patient might bene t, and two Clinical trials con rming the outcome improvement.